Search results (644)
« Back to NewsWhy do we need sleep? Oxford researchers find the answer may lie in mitochondria
18 July 2025
New study uncovers how a metabolic “overload” in specialised brain cells triggers the need to sleep.
Certain chronic health conditions associated with increased risk of dementia – new study
17 July 2025
Developing cardiovascular, mental health and neurological-related illnesses before the age of 70 is associated with a greater risk of dementia later in life, with the more of these conditions accumulated the greater the risk, according to a new study by the University of Oxford.
New £50m MRC Centre launched to study how environmental exposures cause chronic inflammatory diseases
16 July 2025
A new Medical Research Council Centre of Research Excellence (MRC CoRE) will investigate how the environment interacts with our immune system to trigger chronic inflammatory diseases, such as asthma, chronic obstructive pulmonary disorder (COPD) and inflammatory bowel disease (IBD).
Study reveals how HIV-1 breaches the cell’s most guarded barrier
11 July 2025
In a new study from NDM’s Division of Structural Biology, researchers have found out how HIV-1 breaches the cell’s most guarded barrier, revealing the determinants that control the nuclear import of HIV-1.
What Elio can help teach us about eye patching, stigma and the developing brain
11 July 2025
Disney Pixar’s latest film, Elio, follows a familiar-sounding character, a lovable and imaginative young hero who dreams of finding a place where he truly belongs. But amid the colour and chaos of the film’s outer space setting, one subtle detail stands out: Elio wears an eye patch.
Ethnic disparities persist in COVID-19 and cardiovascular disease
7 July 2025
A new study has found that people from non-White ethnic backgrounds in England and Wales continued to be disproportionately impacted by severe outcomes after COVID-19 such as cardiovascular disease.
First of its kind study for children with arthritis reveals possible new disease targets
4 July 2025
Researchers have been able to see what happens in the inflamed joints of children with arthritis, giving insight into why treatments affect children differently.
New tool allows researchers to track how mutations arise in tissues
3 July 2025
Researchers at the MRC Weatherall Institute of Molecular Medicine and the German Cancer Research Center (DKFZ) have developed a new method to analyse how our tissues evolve as we age.
Parkinson’s drug effective in treating persistent depression
30 June 2025
A drug used for Parkinson’s disease has been shown to be effective in reducing the symptoms of difficult to treat depression, in a study led by the University of Oxford.
Oxford to lead new £50m MRC Centre to develop brain stimulation device-based therapies
27 June 2025
A new Medical Research Council Centre of Research Excellence (MRC CoRE) aims to develop brain stimulation devices to treat conditions such as Parkinson’s, dementia, stroke and childhood epilepsy.
Academic leaders respond to Medical Research Council call for urgent action on GP research workforce
27 June 2025
UK academics call for urgent action to protect the academic GP workforce as government commits £29bn to shift NHS care from hospitals to community. New recommendations aim to safeguard world-leading primary care research.
How do vaccines reduce the risk of dementia?
26 June 2025
A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory syncytial virus (RSV) is associated with a 29% reduction in dementia risk in the following 18 months. The findings suggest a novel explanation for how vaccines produce this effect.
‘Single shot’ malaria vaccine delivery system could transform global immunisation
26 June 2025
Oxford researchers have developed programmable microcapsules to deliver vaccines in stages, potentially eliminating the need for booster shots and increasing immunisation coverage in hard-to-reach communities.
Alan Davidson Foundation renews funding for ground-breaking motor neuron disease research at Oxford
20 June 2025
As part of its renewed commitment, the Alan Davidson Foundation will continue to fund a full-time project manager to facilitate the ongoing coordination and growth of the ACORN study. The foundation is also contributing to the cost of a research fellow to support the next phase of the project.
Identification of a new metabolic axis underpinning cardiac dysfunction in diabetes
19 June 2025
A new publication from Department of Physiology, Anatomy and Genetics identifies a new metabolic axis which explains why the diabetic heart becomes fatty.
Oxford neurosurgeon secures nearly £2 million for brain cancer trial
17 June 2025
Associate Professor Puneet Plaha of the Nuffield Department of Surgical Sciences has been awarded a £1.98 million NIHR Health Technology Assessment (HTA) grant to lead a five-year clinical trial addressing one of the most critical questions in brain cancer care.
New consortium to make UK a world leader in AI drug discovery
10 June 2025
A new consortium, co-led by NDM researchers, has just been announced, aiming to make the UK a leader in artificial intelligence-driven drug discovery. The ‘OpenBind’ consortium will slash the cost of drug discovery and development by as much as £100 billion.
Early-career researcher wins £1.2 million Wellcome award
10 June 2025
Mr Keaton Jones from the Nuffield Department of Surgical Sciences has secured a prestigious Wellcome Early-Career Award worth £1.2 million. His research will investigate the role of macrophages, a type of immune cell, and their metabolism in driving immunotherapy resistance in pancreatic cancer.
New research reveals druggable target arising from chromosomal rearrangement in aggressive leukaemia
10 June 2025
Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
Oxford vaccine against deadly Nipah virus granted European Medicines Agency PRIME designation
9 June 2025
The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.